Project Details
Description
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/19 → 11/1/23 |
Funding
- FIBROGEN, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.